Clinically Meaningful Outcomes in Early Alzheimer Disease: A Consortia-Driven Approach to Identifying What Matters to Patients

Background: Numerous statistically derived composite measures have recently been proposed as clinical outcome assessments (COAs) for clinical trials in the early stages of Alzheimer disease. Critical Path Institute’s Coalition Against Major Diseases (CAMD) advanced a proposed statistically derived composite measure to regulatory agencies with the goal of qualifying it as a COA for pre-dementia trials. In response to FDA’s requirement to demonstrate that proposed COAs are meaningful to patients, this project aimed to identify the most important cognition-related concerns patients and informants report early in the disease and determine how this information maps to what is assessed by several statistically derived composite measures. Methods: Leveraging qualitative research completed by Critical Path Institute’s Patient-Reported Outcome Consortium, CAMD utilized a summary report that included frequency grids of reported concerns of amnestic mild cognitive impairment patients and their informants, as well as the narrative transcripts from focus groups. Transcripts were reviewed and analyzed to identify which cognitive domains the patient- and informant-reported concerns mapped onto. The results were then compared to see how well these cognitive domains were represented in various statistically derived composite measures. Results: The patient- and informant-reported concerns primarily mapped to the cognitive domains of episodic memory and, secondarily, orientation and language. Depending on the specified composite, there were varying levels of alignment between their subcomponents and these cognitive domains. Conclusion: Through secondary analyses of existing qualitative data, this study examined several statistically derived composite measures and found that they generally capture cognitive domains that reflect aspects of day-to-day functioning that patients and informants consider meaningful.

[1]  Jeffrey Cummings,et al.  ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  T. Krahnke,et al.  Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies , 2016, Alzheimer's Research & Therapy.

[3]  Mark Forrest Gordon,et al.  Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase , 2016, Alzheimer's & Dementia.

[4]  Draft guideline on the clinical investigation of medicines 4 for the treatment of Alzheimer ’ s disease and other 5 dementias 6 Draft 7 , 2016 .

[5]  E. Siemers,et al.  A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). , 2015, The journal of prevention of Alzheimer's disease.

[6]  D. Harvey,et al.  Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease , 2015, Alzheimer's & Dementia.

[7]  M. Colin Ard,et al.  Optimal composite scores for longitudinal clinical trials under the linear mixed effects model , 2016 .

[8]  Kaori Ito,et al.  Development of a straightforward and sensitive scale for MCI and early AD clinical trials , 2015, Alzheimer's & Dementia.

[9]  A. Fagan,et al.  Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease , 2015, Alzheimer's & Dementia.

[10]  Laurie Burke,et al.  Patient-Focused Drug Development: A New Direction for Collaboration , 2015, Medical care.

[11]  Karen L. Price,et al.  Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. , 2014, Journal of Alzheimer's disease : JAD.

[12]  Richard J. Caselli,et al.  Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools? , 2014, Alzheimer's & Dementia.

[13]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[14]  D. Shera,et al.  VALIDATION OF NOVEL COMPOSITE OUTCOME MEASURES FOR PRE-DEMENTIA ALZHEIMER'S DISEASE , 2014, Alzheimer's & Dementia.

[15]  N. Raghavan,et al.  RETROFITTING EXISTING TOOLS ACROSS THE ALZHEIMER'S DISEASE SPECTRUM , 2014, Alzheimer's & Dementia.

[16]  P. Annas,et al.  Psychometric evaluation of ADAS‐Cog and NTB for measuring drug response , 2014, Acta neurologica Scandinavica.

[17]  A. Fleisher,et al.  The neuropsychology of normal aging and preclinical Alzheimer's disease , 2014, Alzheimer's & Dementia.

[18]  C. Jack,et al.  Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases , 2013, Therapeutic innovation & regulatory science.

[19]  A. Berger,et al.  Psychometric features of the ADAS-Cog: Identifying a potential cognition endpoint for prodromal Alzheimer's disease , 2013, Alzheimer's & Dementia.

[20]  J. Vilalta-Franch,et al.  Factors Associated With the Variability in Caregiver Assessments of the Capacities of Patients With Alzheimer Disease , 2013, Journal of geriatric psychiatry and neurology.

[21]  Nandini Raghavan,et al.  The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials , 2013, Alzheimer's & Dementia.

[22]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[23]  J. Lucas,et al.  Diagnostic accuracy of the MMSE in detecting probable and possible Alzheimer's disease in ethnically diverse highly educated individuals: an analysis of the NACC database. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.

[24]  Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time , 2012, Alzheimer's Research & Therapy.

[25]  Clifford R Jack,et al.  Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.

[26]  L. Burke,et al.  The Patient‐Reported Outcome (PRO) Consortium: Filling Measurement Gaps for PRO End Points to Support Labeling Claims , 2011, Clinical pharmacology and therapeutics.

[27]  Bruno Vellas,et al.  Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer’s disease trials , 2011, Alzheimer's & Dementia.

[28]  S. Chieffi,et al.  Anosognosia for memory deficit in amnestic mild cognitive impairment and Alzheimer's disease , 2011, International journal of geriatric psychiatry.

[29]  R. Petersen Clinical practice. Mild cognitive impairment. , 2011, The New England journal of medicine.

[30]  Viswanath Devanarayan,et al.  Derivation of a New ADAS-cog Composite Using Tree-based Multivariate Analysis: Prediction of Conversion From Mild Cognitive Impairment to Alzheimer Disease , 2011, Alzheimer disease and associated disorders.

[31]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[32]  Jessica C. Payne-Murphy,et al.  Trajectory of mild cognitive impairment onset , 2008, Journal of the International Neuropsychological Society.

[33]  Martin Koller,et al.  A neuropsychological test battery for use in Alzheimer disease clinical trials. , 2007, Archives of neurology.

[34]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[35]  R. Petersen,et al.  Mild cognitive impairment , 2006, The Lancet.

[36]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[37]  Kimberly Schafer,et al.  Interobserver Disagreements on Clinical Dementia Rating Assessment: Interpretation and Implications for Training , 2001, Alzheimer disease and associated disorders.

[38]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[39]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[40]  T. Kurosaki,et al.  Measurement of functional activities in older adults in the community. , 1982, Journal of gerontology.

[41]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.